Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights

Table 3

Characteristics of patients in the evaluated studies.

Study

Median age/Male patients; %

ECOG > 0; %

Diffuse Histology; %

Primary lesion GEJ junction; %

Prior Surgery; %

Number of metastatic sites >2; %

Peritoneal metastasis; %

> II previous lines of treatment; %

Previous Ram.; %

E

P

E

P

E

P

E

P

E

P

E

P

E

P

E

P

E

P

Li et al 2016

58/75

58/75

73

83

NR

NR

22

23

69°

74°

21

22

24

27

34

36

NR

NR

TAGS

64/75

63/69

64

60

16

12

29

28

44°

44°

54

58

26

31

63

62

34

32

ATTRACTION-2

62/69

61/73

71

71

NR

NR

NR

NR

60°

64°

75°°

73°°

19

26

79

72

11

13

E: experimental arm; P: placebo arm; NR: Not reported; GEJ: Gastroesophageal; Ram: Ramucirumab
° Gastrectomy
°° ≥2 organs with metastases